EP1315512A4 - Adenoviral targeting and manipulation of immune system response using targeting peptides - Google Patents
Adenoviral targeting and manipulation of immune system response using targeting peptidesInfo
- Publication number
- EP1315512A4 EP1315512A4 EP01970682A EP01970682A EP1315512A4 EP 1315512 A4 EP1315512 A4 EP 1315512A4 EP 01970682 A EP01970682 A EP 01970682A EP 01970682 A EP01970682 A EP 01970682A EP 1315512 A4 EP1315512 A4 EP 1315512A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- disclosed
- targeting
- peptides
- novel
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23126600P | 2000-09-08 | 2000-09-08 | |
US231266P | 2000-09-08 | ||
US76510101A | 2001-01-17 | 2001-01-17 | |
US765101 | 2001-01-17 | ||
PCT/US2001/028045 WO2002020724A2 (en) | 2000-09-08 | 2001-09-07 | Adenoviral targeting and manipulation of immune system response using targeting peptides |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1315512A2 EP1315512A2 (en) | 2003-06-04 |
EP1315512A4 true EP1315512A4 (en) | 2005-11-09 |
Family
ID=26924954
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08016646A Withdrawn EP2028187A1 (en) | 2000-09-08 | 2001-09-07 | Human and mouse targeting peptides identified by phage display |
EP01970671A Withdrawn EP1315965A4 (en) | 2000-09-08 | 2001-09-07 | Methods and compositions for in vitro targeting |
EP01968603A Expired - Lifetime EP1322755B1 (en) | 2000-09-08 | 2001-09-07 | Human and mouse targeting peptides identified by phage display |
EP01970682A Withdrawn EP1315512A4 (en) | 2000-09-08 | 2001-09-07 | Adenoviral targeting and manipulation of immune system response using targeting peptides |
EP01970681A Withdrawn EP1315830A4 (en) | 2000-09-08 | 2001-09-07 | Compositions and methods for targeting peptides in humans in vivo |
EP01968683A Withdrawn EP1315840A4 (en) | 2000-09-08 | 2001-09-07 | Biopanning and rapid analysis of selective interactive ligands (brasil) |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08016646A Withdrawn EP2028187A1 (en) | 2000-09-08 | 2001-09-07 | Human and mouse targeting peptides identified by phage display |
EP01970671A Withdrawn EP1315965A4 (en) | 2000-09-08 | 2001-09-07 | Methods and compositions for in vitro targeting |
EP01968603A Expired - Lifetime EP1322755B1 (en) | 2000-09-08 | 2001-09-07 | Human and mouse targeting peptides identified by phage display |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01970681A Withdrawn EP1315830A4 (en) | 2000-09-08 | 2001-09-07 | Compositions and methods for targeting peptides in humans in vivo |
EP01968683A Withdrawn EP1315840A4 (en) | 2000-09-08 | 2001-09-07 | Biopanning and rapid analysis of selective interactive ligands (brasil) |
Country Status (7)
Country | Link |
---|---|
EP (6) | EP2028187A1 (en) |
JP (6) | JP2004536020A (en) |
AT (1) | ATE478141T1 (en) |
CA (5) | CA2421195A1 (en) |
DE (1) | DE60142840D1 (en) |
PT (1) | PT1322755E (en) |
WO (4) | WO2002020724A2 (en) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999046284A2 (en) * | 1998-03-13 | 1999-09-16 | The Burnham Institute | Molecules that home to various selected organs or tissues |
US7420030B2 (en) | 2000-09-08 | 2008-09-02 | The Board Of Regents Of The University Of Texas System | Aminopeptidase A (APA) targeting peptides for the treatment of cancer |
WO2002020769A1 (en) * | 2000-09-08 | 2002-03-14 | Board Of Regents, The University Of Texas System | Human and mouse targeting peptides identified by phage display |
US20040170955A1 (en) | 2000-09-08 | 2004-09-02 | Wadih Arap | Human and mouse targeting peptides identified by phage display |
US7452964B2 (en) | 2001-09-07 | 2008-11-18 | Board Of Regents, The University Of Texas System | Compositions and methods of use of targeting peptides against placenta and adipose tissues |
US7671010B2 (en) | 2002-08-30 | 2010-03-02 | The Board Of Regents Of The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer |
US8507445B2 (en) * | 2001-09-07 | 2013-08-13 | Board Of Regents, The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer |
WO2003070749A2 (en) | 2002-02-15 | 2003-08-28 | Northwestern University | Self-assembly of peptide-amphiphile nanofibers under physiological conditions |
EP1346729A1 (en) * | 2002-03-19 | 2003-09-24 | Cardiovascular Research Institute Maastricht | Targeting of myocardial angiogenesis through CD13/APN |
US9321992B2 (en) | 2002-06-14 | 2016-04-26 | Case Western Reserve University | Cell targeting methods and compositions |
AU2002364501A1 (en) * | 2002-08-30 | 2004-03-19 | Board Of Regents, The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer |
US7554021B2 (en) | 2002-11-12 | 2009-06-30 | Northwestern University | Composition and method for self-assembly and mineralization of peptide amphiphiles |
WO2004084950A2 (en) * | 2003-03-24 | 2004-10-07 | Case Western Reserve University | Cell targeting methods and compositions |
WO2004093807A2 (en) * | 2003-04-22 | 2004-11-04 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Somatostatin vectors |
US20040248109A1 (en) * | 2003-06-09 | 2004-12-09 | Lawrence Greenfield | Methods for selecting protein binding moieties |
US20050187161A1 (en) * | 2003-09-12 | 2005-08-25 | Board Of Regents, The University Of Texas System | Biopanning as an approach to study the pathogenesis of and produce novel treatment modalities for invasive Aspergillosis |
JP2011239784A (en) * | 2003-12-04 | 2011-12-01 | Perseus Proteomics Inc | Acquisition of antibody against cell surface antigen, and antigen identification of the same |
JP4870348B2 (en) * | 2003-12-04 | 2012-02-08 | 株式会社ペルセウスプロテオミクス | Antibody acquisition and antigen identification against cell surface antigens |
CN102225964A (en) | 2003-12-05 | 2011-10-26 | 西北大学 | Self-assembling peptide amphiphiles and related methods for growth factor delivery |
US8377484B1 (en) * | 2004-05-06 | 2013-02-19 | Maria V. Tsiper | Tumor encapsulation for prevention and treatment of metastatic cancer disease |
CN1294418C (en) * | 2004-08-09 | 2007-01-10 | 中国人民解放军南京军区南京总医院 | Method and reagent box for inspecting mycelian protein antibody of white candida |
GB0422431D0 (en) * | 2004-10-08 | 2004-11-10 | Affitech As | Method |
ITRM20040568A1 (en) * | 2004-11-18 | 2005-02-18 | Uni Degli Studi Di Roma Tor Vergata | USE OF THE "PHAGE DISPLAY" TECHNIQUE FOR THE IDENTIFICATION OF PEPTIDES WITH CAPACITY OF STAMIN CELLS / PROGENITOR, PEPTIDES SO OBTAINED AND THEIR USES. |
EP1874800A4 (en) * | 2005-04-26 | 2009-11-18 | Karyon Ctt Ltd | Diagnostic and therapeutic agents |
US8168181B2 (en) | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
US7989160B2 (en) | 2006-02-13 | 2011-08-02 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptide sequences involved in the process of bone remodeling |
EP2338898A1 (en) * | 2006-03-09 | 2011-06-29 | The Board of Regents of the University of Texas System | Compositions and methods related to profiling a plurality of cell lines based on peptide binding |
CN101951953A (en) * | 2007-02-27 | 2011-01-19 | 株式会社未来创药研究所 | Contain the pharmaceutical composition of anti-GRP78 antibody as effective ingredient |
US8076295B2 (en) | 2007-04-17 | 2011-12-13 | Nanotope, Inc. | Peptide amphiphiles having improved solubility and methods of using same |
WO2009036167A1 (en) * | 2007-09-14 | 2009-03-19 | Vanderbilt University | Targeting of notch3 receptor function for cancer therapy |
RU2636046C2 (en) * | 2009-01-12 | 2017-11-17 | Сайтомкс Терапьютикс, Инк | Modified antibodies composition, methods of production and application |
KR20120012811A (en) | 2009-04-13 | 2012-02-10 | 노오쓰웨스턴 유니버시티 | Novel peptide-based scaffolds for cartilage regeneration and methods for their use |
EP2683393B1 (en) | 2011-02-11 | 2018-04-11 | The Regents of The University of Michigan | Tripeptide compositions and their use for treatment of diabetes |
US20150105274A1 (en) * | 2012-02-10 | 2015-04-16 | Phylogica Limited | Methods for the Characterisation of Interaction Sites on Target Proteins |
WO2013149237A1 (en) * | 2012-03-30 | 2013-10-03 | Board Of Regents, The University Of Texas System | Targeting intracellular organelle zip codes with functional homing ligands from cell-internalizing phage combinatorial libraries |
CA2928851A1 (en) | 2012-07-19 | 2014-01-23 | Alethia Biotherapeutics Inc. | Anti-siglec-15 antibodies |
GB201308745D0 (en) * | 2013-05-15 | 2013-06-26 | Imp Innovations | Bacteriophage |
CN103497236B (en) * | 2013-09-25 | 2017-05-10 | 浙江省医学科学院 | Specific heptapeptide targeting to WISP-1 protein and application thereof |
GB2522412A (en) * | 2014-01-22 | 2015-07-29 | Agency Science Tech & Res | Antimicrobial peptidomimetics |
WO2015124540A1 (en) | 2014-02-19 | 2015-08-27 | F. Hoffmann-La Roche Ag | Blood brain barrier shuttle |
NZ726112A (en) * | 2014-05-19 | 2021-07-30 | Valo Therapeutics Oy | Coated adenoviruses for immunotherapy |
CN105769909A (en) * | 2016-05-13 | 2016-07-20 | 云南舜喜再生医学工程有限公司 | Hemostix and method for directly obtaining cytokine-containing serum |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
KR101921836B1 (en) | 2017-11-23 | 2018-11-26 | 서울대학교병원 | Method, composition and kit for regulating differentiation of skin adult stem cell |
WO2020068815A1 (en) * | 2018-09-25 | 2020-04-02 | Emory University | Nucleic acids for cell recognition and integration |
CN109137086A (en) * | 2018-10-16 | 2019-01-04 | 梁耀极 | A kind of banking process of the full length mRNA sequencing of improvement |
US20230131559A1 (en) | 2019-07-10 | 2023-04-27 | Universidade Federal de Uberlândia | Recombinant peptides that bind to a tumour-specific antibody for breast cancer and use |
EP3767628B1 (en) | 2019-07-18 | 2024-03-27 | Bayer Aktiengesellschaft | Selection of antibodies / antibody fragments |
AU2020407501A1 (en) * | 2019-12-17 | 2022-08-04 | Mie University | Methods and compositions for evaluating and treating fibrosis |
GB202211043D0 (en) * | 2022-07-28 | 2022-09-14 | Univ Birmingham | Peptide agonist |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999046284A2 (en) * | 1998-03-13 | 1999-09-16 | The Burnham Institute | Molecules that home to various selected organs or tissues |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (en) | 1970-11-10 | 1977-09-15 | Organon Nv | PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US4957939A (en) | 1981-07-24 | 1990-09-18 | Schering Aktiengesellschaft | Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging |
US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
US5206347A (en) | 1985-08-06 | 1993-04-27 | La Jolla Cancer Research Foundation | Isolation and use of receptors binding to a peptide column |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5252296A (en) | 1990-05-15 | 1993-10-12 | Chiron Corporation | Method and apparatus for biopolymer synthesis |
EP0525132B1 (en) | 1991-02-14 | 1996-01-03 | Baxter International Inc. | Binding of recognizing substances to liposomes |
US5603872A (en) | 1991-02-14 | 1997-02-18 | Baxter International Inc. | Method of binding recognizing substances to liposomes |
US5329028A (en) | 1992-08-05 | 1994-07-12 | Genentech, Inc. | Carbohydrate-directed cross-linking reagents |
AU684510B2 (en) * | 1993-05-28 | 1997-12-18 | Chiron Corporation | Method for selection of biologically active peptide sequences |
US5492807A (en) | 1993-11-19 | 1996-02-20 | Santi; Daniel V. | Method of obtaining diagnostic reagents, assays and therapeutics based on clinical manifestations of a disease |
US5622699A (en) | 1995-09-11 | 1997-04-22 | La Jolla Cancer Research Foundation | Method of identifying molecules that home to a selected organ in vivo |
US6068829A (en) | 1995-09-11 | 2000-05-30 | The Burnham Institute | Method of identifying molecules that home to a selected organ in vivo |
ATE195181T1 (en) * | 1995-09-11 | 2000-08-15 | Jolla Cancer Res Found | MOLECULES THAT ARE FOUND IN SELECTED ORGANS OR TISSUES INVIVO AND METHOD FOR THEIR IDENTIFICATION |
EP1109897A1 (en) * | 1998-09-07 | 2001-06-27 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Method for selecting peptides for the targeted transport of drugs and markers, and peptides discovered using said method |
-
2001
- 2001-09-07 CA CA002421195A patent/CA2421195A1/en not_active Abandoned
- 2001-09-07 CA CA002421200A patent/CA2421200A1/en not_active Abandoned
- 2001-09-07 JP JP2002525731A patent/JP2004536020A/en not_active Withdrawn
- 2001-09-07 PT PT01968603T patent/PT1322755E/en unknown
- 2001-09-07 JP JP2002525828A patent/JP2004530404A/en not_active Withdrawn
- 2001-09-07 CA CA002421191A patent/CA2421191A1/en not_active Abandoned
- 2001-09-07 CA CA002421380A patent/CA2421380A1/en not_active Abandoned
- 2001-09-07 EP EP08016646A patent/EP2028187A1/en not_active Withdrawn
- 2001-09-07 AT AT01968603T patent/ATE478141T1/en not_active IP Right Cessation
- 2001-09-07 WO PCT/US2001/028045 patent/WO2002020724A2/en not_active Application Discontinuation
- 2001-09-07 WO PCT/US2001/028124 patent/WO2002020822A2/en not_active Application Discontinuation
- 2001-09-07 EP EP01970671A patent/EP1315965A4/en not_active Withdrawn
- 2001-09-07 DE DE60142840T patent/DE60142840D1/en not_active Expired - Lifetime
- 2001-09-07 EP EP01968603A patent/EP1322755B1/en not_active Expired - Lifetime
- 2001-09-07 JP JP2002525730A patent/JP2004533803A/en not_active Withdrawn
- 2001-09-07 WO PCT/US2001/027702 patent/WO2002020722A2/en not_active Application Discontinuation
- 2001-09-07 WO PCT/US2001/028044 patent/WO2002020723A2/en not_active Application Discontinuation
- 2001-09-07 EP EP01970682A patent/EP1315512A4/en not_active Withdrawn
- 2001-09-07 EP EP01970681A patent/EP1315830A4/en not_active Withdrawn
- 2001-09-07 CA CA002421271A patent/CA2421271A1/en not_active Abandoned
- 2001-09-07 JP JP2002525729A patent/JP2004515751A/en not_active Withdrawn
- 2001-09-07 EP EP01968683A patent/EP1315840A4/en not_active Withdrawn
-
2010
- 2010-12-13 JP JP2010277247A patent/JP2011120587A/en not_active Withdrawn
-
2011
- 2011-11-09 JP JP2011245272A patent/JP5591209B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999046284A2 (en) * | 1998-03-13 | 1999-09-16 | The Burnham Institute | Molecules that home to various selected organs or tissues |
Non-Patent Citations (4)
Title |
---|
ARAP W ET AL: "CANCER TREATMENT BY TARGETED DRUG DELIVERY TO TUMOR VASCULATURE IN A MOUSE MODEL", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 279, 16 January 1998 (1998-01-16), pages 377 - 380, XP000857470, ISSN: 0036-8075 * |
ELLERBY H M ET AL: "ANTI-CANCER ACTIVITY OF TARGETED PRO-APOPTOTIC PEPTIDES", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 5, no. 9, September 1999 (1999-09-01), pages 1032 - 1038, XP000995556, ISSN: 1078-8956 * |
RAJOTTE D ET AL: "MEMBRANE DIPEPTIDASE IS THE RECEPTOR FOR A LUNG-TARGETING PEPTIDE IDENTIFIED BY IN VIVO PHAGE DISPLAY", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 274, no. 17, 23 April 1999 (1999-04-23), pages 11593 - 11598, XP000869582, ISSN: 0021-9258 * |
WANG H ET AL: "Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 18 JAN 2000, vol. 97, no. 2, 18 January 2000 (2000-01-18), pages 847 - 852, XP001206541, ISSN: 0027-8424 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1315512A4 (en) | Adenoviral targeting and manipulation of immune system response using targeting peptides | |
WO2001051604A3 (en) | Methods for identifying anti-cancer drug targets | |
AU5464000A (en) | Recombinant adenoviral vectors for cell specific infection and genome integration and expressing chimeric fiber proteins | |
AP2004002986A0 (en) | Use of biologically active HIV-1 TAT, fragments or derivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases | |
AU5161800A (en) | Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases | |
CY1107351T1 (en) | ARGININ'S MUTUALLY MUTUAL FORMULATED FORM | |
AU688101B2 (en) | Live vaccine for the treatment of tumour diseases | |
ATE287958T1 (en) | IMPROVED CANCER THERAPY | |
EP1070122A4 (en) | Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery | |
ES2439954T3 (en) | Recombinant viral vectors for prevention and protection against alphavirus infection | |
DE60129069D1 (en) | Hepatitis B virus vectors for gene therapy | |
Sangro et al. | Gene therapy of hepatocellular carcinoma and gastrointestinal tumors | |
WO2003092598A3 (en) | Treatment for pompe disease | |
ATE239749T1 (en) | PHOSPHORUS-CONTAINING DENDRIMERS AS TRANSFECTION AGENT | |
EP1593742A3 (en) | Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection | |
De Giovanni et al. | The prospects for cancer gene therapy | |
EP1494705B1 (en) | A composition and method for killing of tumours | |
ATE210990T1 (en) | THERAPEUTIC VIRAL AGENT WHICH STOPS THE PROGRESSION OF TUMORS | |
Sikora et al. | Genetic drug activation strategies for breast cancer | |
Muraca et al. | Cancer Gene Therapy: Current Limitations and Future Potential Is It Just a Matter of Time? | |
MX9708615A (en) | Animal gene therapy. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030307 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: PASQUALINI, RENATA Inventor name: ARAP, WADIH |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20050923 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20051217 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: PASQUALINI, RENATA Inventor name: ARAP, WADIH |